Researching Ways to Prevent Cancer
ImmunityBio is working with the National Cancer Institute on the largest Lynch syndrome cancer prevention study in the U.S. People with hereditary Lynch syndrome can develop colorectal cancer decades earlier than average, and have increased risk of developing additional cancers.
Finding Better Treatments for Bladder Cancer
We are pleased to report that the FDA has accepted for review our BLA for N-803 + BCG for BCG-Unresponsive NMIBC CIS. If approved, N-803 plus BCG would be the first immunotherapy combination for this indication in 23 years that can be delivered directly to the bladder to induce natural killer cells and T cells.
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.
We are committed to increasing diversity in clinical trials
Increasing diversity and fostering inclusion among clinical trial participants ensures that trial results help reduce current disparities in healthcare.
Solutions for PatientsMany therapies for treating cancer and infectious disease severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.
Opportunities for Trial InvestigatorsImmunotherapies and cell therapies are key to future cancer treatments. Our investigational IL-15 superagonist, N-803, and NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.
Solutions for Research ScientistsOur NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
Smart Therapies for Difficult Diseases®
Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.
Investigational Cancer Therapies
ImmunityBio’s platform addresses the entire immune system beyond the limitations of chimeric antigen receptor T-cell (CAR-T) therapies and checkpoint inhibitors by activating the natural killer cell, T cells, macrophages, and inducing memory through dendritic cells. Clinical trials orchestrating these unique therapies, which harness both the innate and adaptive immune system, are in progress across multiple tumor types.
Investigational Viral Therapies
Infected cells, like cancer cells, can be exposed to enable recognition and killing by our natural killer cell and T cell platforms. Current clinical trials addressing HIV, COVID, and infectious diseases are in progress. The potential to administer these vaccines orally will enable greater global access.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
A Robust Clinical Pipeline
ImmunityBio's investigational immunotherapies are currently being studied for cancer and infectious disease in a range of clinical trials at various stages.
Latest News & Events
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
CULVER CITY, Calif., May 22, 2023 - ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today...
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
The Phase 2b cancer vaccine trial will study a multiple vaccination approach called ‘Tri-Ad5’ that uses three...
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
CULVER CITY, Calif., April 24, 2023 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today...